Valuation: Annexon, Inc.

Market Cap 950M 830M 766M 706M 1.33B 91.51B 1.36B 9.16B 3.6B 44.82B 3.57B 3.49B 154B P/E 2026 *
-6.18x
P/E 2027 * -7.24x
Enterprise Value 856M 748M 690M 636M 1.2B 82.42B 1.23B 8.25B 3.24B 40.36B 3.21B 3.14B 139B EV / Sales 2026 *
-
EV / Sales 2027 * 16.1x
Free-Float
93.57%
Yield 2026 *
-
Yield 2027 * -
1 day-1.53%
Current month+1.58%
1 month+17.41%
3 months-11.31%
6 months-4.45%
Current year+15.54%
1 week 5.41
Extreme 5.41
6.58
1 month 4.94
Extreme 4.935
6.58
Current year 4.46
Extreme 4.46
7.18
1 year 2.03
Extreme 2.03
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.81
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 58 01/12/2014
Director/Board Member 65 01/12/2014
Director/Board Member 67 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
11/06/26 Free

Director

65,000 0.0397%
11/06/26 Free

Director

65,000 0.0397%
11/06/26 Free

Director

65,000 0.0397%
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%0.00%+147.86%+56.55% 950M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.65%-2.36%+51.48%+171.07% 23.45B
Weighted average by Cap. -2.80%-2.35%+40.56%+143.75%

Financials

2026 *2027 *
Net sales - 41M 35.83M 33.06M 30.47M 57.44M 3.95B 58.71M 395M 155M 1.93B 154M 151M 6.66B
Net income -189M -165M -152M -140M -264M -18.16B -270M -1.82B -715M -8.89B -708M -693M -30.61B -184M -161M -148M -137M -258M -17.71B -263M -1.77B -697M -8.67B -691M -676M -29.86B
Net Debt -94.47M -82.56M -76.18M -70.22M -132M -9.1B -135M -911M -358M -4.46B -355M -347M -15.34B -292M -255M -235M -217M -409M -28.11B -418M -2.81B -1.11B -13.77B -1.1B -1.07B -47.39B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
93
Date Price Change Volume
17/07/26 $5.800 -1.53% 3,341,464
16/07/26 $5.890 -9.38% 7,711,289
15/07/26 $6.500 +17.12% 8,846,423
14/07/26 $5.550 -1.42% 5,555,931
13/07/26 $5.630 -2.93% 3,040,205
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.800USD
Average target price
14.88USD
Spread / Average Target
+156.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock